Modifications

'''Michael John Cook''' ou '''Michael J. Cook''', en court '''Michael Cook'''.

'''Michael John Cook''' ou '''Michael J. Cook''', en court '''Michael Cook'''.

Michael J. Cook a appris qu'il était atteint de la maladie de Lyme en 2009, après avoir pris sa retraite d'une carrière dans l'industrie des semi-conducteurs, où il a dirigé des équipes de recherche et d'ingénierie de production. Titulaire d'un BSc en physique et en mathématiques, il a appliqué ses compétences analytiques pour étudier de nombreux aspects de la maladie. Depuis 2015, il a publié des articles sur l'inexactitude des temps d'attachement déclarés des tiques et le manque de fiabilité des tests commerciaux de Lyme. Il a présenté ses travaux lors de conférences sur la maladie de Lyme à Paris et à Boston, ainsi qu'aux membres de la Chambre des communes, aux autorités médicales et locales, aux agences environnementales et sanitaires.<br><br>Il défend les intérêts des patients atteints de Lyme et a mené une enquête technique sur un laboratoire de référence britannique, qui a été fermé. Il est membre du conseil d'administration de l'organisation caritative Vis-a-Vis Symposium, qui fait venir des experts du monde entier pour parler aux professionnels de la santé du Royaume-Uni. Il continue à travailler sur divers aspects de la [[maladie de Lyme]] et à participer avec des patients, des groupes de soutien, des organisations médicales britanniques et des agences et comités gouvernementaux.<ref>https://www.lymeresourcecentre.com/about-us/mcook <br>Michael J Cook, was diagnosed with Lyme disease in 2009 after retiring from a career in the semiconductor industry, leading teams in research and production engineering. With a BSc in Physics and Mathematics, he has applied his analytical skills to investigate many aspects of the disease. Since 2015, he has published papers on the inaccuracy of stated tick attachment times and the unreliability of commercial Lyme testing. He has presented his work at Lyme conferences in Paris and Boston as well as to the members of the House of Commons, medical and local government, environmental and health agencies.<br><br>He works as an advocate for Lyme patients and carried out the technical investigation of a UK Lyme Reference Laboratory, which was closed down. He is a trustee of the Vis-a-Vis Symposium charity which brings experts from around the world to speak to UK medical professionals, and continues to work on various aspects of Lyme disease and participating with patients, support groups, UK medical organisations and government agencies and committees.</ref>

Michael J. Cook a appris qu'il était atteint de la maladie de Lyme en 2009, après avoir pris sa retraite d'une carrière dans l'industrie des semi-conducteurs, où il a dirigé des équipes de recherche et d'ingénierie de production. Titulaire d'un BSc en physique et en mathématiques, il a appliqué ses compétences analytiques pour étudier de nombreux aspects de la maladie. Depuis 2015, il a publié des articles sur l'inexactitude des temps d'attachement déclarés des tiques et le manque de fiabilité des tests commerciaux de Lyme. Il a présenté ses travaux lors de conférences sur la [[maladie de Lyme]] à Paris et à Boston, ainsi qu'aux membres de la Chambre des communes, aux autorités médicales et locales, aux agences environnementales et sanitaires.<br><br>Il défend les intérêts des patients atteints de Lyme et a mené une enquête technique sur un laboratoire de référence britannique, qui a été fermé. Il est membre du conseil d'administration de l'organisation caritative Vis-a-Vis Symposium, qui fait venir des experts du monde entier pour parler aux professionnels de la santé du Royaume-Uni. Il continue à travailler sur divers aspects de la [[maladie de Lyme]] et à participer avec des patients, des groupes de soutien, des organisations médicales britanniques et des agences et comités gouvernementaux.<ref>https://www.lymeresourcecentre.com/about-us/mcook <br>Michael J Cook, was diagnosed with Lyme disease in 2009 after retiring from a career in the semiconductor industry, leading teams in research and production engineering. With a BSc in Physics and Mathematics, he has applied his analytical skills to investigate many aspects of the disease. Since 2015, he has published papers on the inaccuracy of stated tick attachment times and the unreliability of commercial Lyme testing. He has presented his work at Lyme conferences in Paris and Boston as well as to the members of the House of Commons, medical and local government, environmental and health agencies.<br><br>He works as an advocate for Lyme patients and carried out the technical investigation of a UK Lyme Reference Laboratory, which was closed down. He is a trustee of the Vis-a-Vis Symposium charity which brings experts from around the world to speak to UK medical professionals, and continues to work on various aspects of Lyme disease and participating with patients, support groups, UK medical organisations and government agencies and committees.</ref>

== Publications scientifiques de Michael J. Cook ==

== Publications scientifiques de Michael J. Cook ==

Publié dans la revue PLoS One. L'article intégral a été disponible le 15 avril 2019.

Publié dans la revue PLoS One. L'article intégral a été disponible le 15 avril 2019.

Auteurs: [[John Shearer Lambert|John S Lambert]]^1,2*, Michael John Cook³, John Eoin Healy⁴, Ross Murtagh¹, Gordana Avramovic^1,2, Sin Hang Lee⁵

Auteurs: [[John Shearer Lambert|John S Lambert]]^1,2*, Michael John Cook³, John Eoin Healy⁴, Ross Murtagh¹, Gordana Avramovic^1,2, [[Sin Hang Lee]]⁵

Affiliations des auteurs:

Affiliations des auteurs:

[...]

[...]

<ref>https://pubmed.ncbi.nlm.nih.gov/30986208/ "Metagenomic 16S rRNA gene sequencing survey of Borrelia species in Irish samples of Ixodes ricinus ticks"<br>John S Lambert, Michael John Cook, John Eoin Healy, Ross Murtagh, Gordana Avramovic, Sin Hang Lee.<br><br>'''Abstract'''<br>The spirochetal bacterium Borrelia miyamotoi is a human pathogen and has been identified in many countries throughout the world. This study reports for the first time the presence of Borrelia miyamotoi in Ireland, and confirms prior work with the detection of B. garinii and B. valaisiana infected ticks. Questing Ixodes ricinus nymph samples were taken at six localities within Ireland. DNA extraction followed by Sanger sequencing was used to identify the species and strains present in each tick. The overall rate of borrelial infection in the Irish tick population was 5%, with a range from 2% to 12% depending on the locations of tick collection. The most prevalent species detected was B. garinii (70%) followed by B. valaisiana (20%) and B. miyamotoi (10%). Knowledge of Borrelia species prevalence is important and will guide appropriate selection of antigens for serology test kit manufacture, help define the risk of infection, and allow medical authorities to formulate appropriate strategies and guidelines for diagnosis and treatment of Borrelia diseases.<br><br>'''Conflict of interest'''<br>SHL is Director of Milford Molecular Diagnostics Laboratory. There are no patents, products in development or marketed products associated with this research to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.</ref>

<ref>https://pubmed.ncbi.nlm.nih.gov/30986208/ "Metagenomic 16S rRNA gene sequencing survey of Borrelia species in Irish samples of Ixodes ricinus ticks"<br>[[John Shearer Lambert|John S Lambert]], Michael John Cook, John Eoin Healy, Ross Murtagh, Gordana Avramovic, Sin Hang Lee.<br><br>'''Abstract'''<br>The spirochetal bacterium Borrelia miyamotoi is a human pathogen and has been identified in many countries throughout the world. This study reports for the first time the presence of Borrelia miyamotoi in Ireland, and confirms prior work with the detection of B. garinii and B. valaisiana infected ticks. Questing Ixodes ricinus nymph samples were taken at six localities within Ireland. DNA extraction followed by Sanger sequencing was used to identify the species and strains present in each tick. The overall rate of borrelial infection in the Irish tick population was 5%, with a range from 2% to 12% depending on the locations of tick collection. The most prevalent species detected was B. garinii (70%) followed by B. valaisiana (20%) and B. miyamotoi (10%). Knowledge of Borrelia species prevalence is important and will guide appropriate selection of antigens for serology test kit manufacture, help define the risk of infection, and allow medical authorities to formulate appropriate strategies and guidelines for diagnosis and treatment of Borrelia diseases.<br><br>'''Conflict of interest'''<br>SHL is Director of Milford Molecular Diagnostics Laboratory. There are no patents, products in development or marketed products associated with this research to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.</ref>

=== Article "Estimates for Lyme borreliosis infections based on models using sentinel canine and human seroprevalence data" ===

=== Article "Estimates for Lyme borreliosis infections based on models using sentinel canine and human seroprevalence data" ===